信達思 CTAS 深 滬
已收盤 10-31 16:00:00 美东时间
183.27
-0.710
-0.39%
華盛通- 最 高184.80
- 今 開183.98
- 成交量 236.27万股
- 最 低 182.70
- 昨 收 183.98
- 總市值 738.58亿
- 52周最高 228.79
- 市盈率 靜 41.64
- 換手率 0.59%
- 52周最低 179.55
- 委 比 -81.22%
- 總股本 4.03亿
- 歷史最高 228.79
- 量 比 1.25
- 振 幅 1.14%
- 歷史最低 -2.825
- 每 手 1
- 風險率 12.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cintas Shareholders Vote on Key Governance Matters
Cintas ( ($CTAS) ) has shared an update. On October 28, 2025, Cintas Corporatio...
11-01 03:17
Cintas's expanded share repurchase program signals confidence, UBS says
Cintas (CTAS) this week increased its share repurchase authorization by $1 billion, bringing the total to $1.7 billion, a move analysts at UBS said signals confidence in the company’s cash generation ...
10-30 03:15
Cintas Adds $1B To Buyback Plan
Cintas also announced that the Board of Directors approved an additional share buyback program under which the Company may buy up to $1.0 billion of Cintas common stock at market prices. This program is in addition to a
10-29 02:08
重新理解凌雄科技(02436.HK)，Physical Al时代DaaS如何重构企业设备管理生态
回望历史，从工业革命的蒸汽机到信息时代的互联网，每一次技术的飞跃都重塑了产业格局，催生了新的商业模式和经济增长点。 如今，AI作为新一轮技术革命的核...
10-10 09:45
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
Five out of seven companies report EPS wins this week: Earnings Scorecard
Stock index futures rose on Friday as discussions on rate cuts continued to be in focus, amid the release of a key inflation gauge. This was after Wall Street finished lower in a roller coaster sessi...
09-26 21:15
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Cintas Earnings Call: Strong Growth and Optimistic Outlook
Cintas (($CTAS)) has held its Q1 earnings call. Read on for the main highlights...
09-26 08:04
JP Morgan Maintains Overweight on Cintas, Lowers Price Target to $230
JP Morgan analyst Andrew Steinerman maintains Cintas (NASDAQ: CTAS) with a Overweight and lowers the price target from $246 to $230.
09-25 21:01
MillerKnoll Shares Are Trading Lower Wednesday: What's Going On?
MillerKnoll reports higher earnings and sales in Q1, sees mixed outlook for Q2. Stock closes down 10.83%.
09-25 04:08
